THBS2 and schistosomiasis: Sm-TSP-2 has proven to be one of the most effective vaccine candidates against schistosomiasis [40, 41] and has successfully undergone a phase I clinical trial [42]; confirmation of the existence of a S. haematobium orthologue is important, therefore, to determine whether a similar (or existing) vaccination strategy might be effective against this species of schistosome.